文献速递骨软组织肉瘤与黑色素瘤

在法国多中心前瞻性队列MelBase中同步放疗对接受全身治疗的黑色素瘤脑转移患者的影响

Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort.
PubMed 文献 · Eur J Cancer · 2019-03-22

基于法国多中心前瞻性队列MelBase中262例不可切除III/IV期黑色素瘤脑转移患者,比较同步放疗组(93例,35%)与未同步放疗组的总生存。中位随访6.9个月,倾向评分加权后同步放疗与更长总生存相关(HR=0.6,95%CI 0.4-0.8,p=0.007),加权后中位OS为15.3个月对6.2个月。

要点

  • 262例黑色素瘤脑转移患者中93例(35%)接受同步放疗。
  • 中位随访6.9个月,同步放疗组中位OS 16.8个月,未同步放疗组6.9个月。
  • 倾向评分加权后同步放疗与更长OS相关(HR=0.6,95%CI 0.4-0.8,p=0.007)。

核心结论

  • 本研究表明,在接受全身治疗的黑色素瘤脑转移患者中,同步放疗可能与死亡风险显著降低40%相关。

研究设计与样本

  • 法国多中心前瞻性队列MelBase前瞻性纳入不可切除III期或IV期黑色素瘤患者,本研究收集262例黑色素瘤脑转移患者的临床数据。
  • 分为接受同步放疗组(cRT组)与未接受同步放疗组(no-cRT组),主要终点为总生存,采用倾向评分加权校正适应证偏倚。

主要发现

  • 262例患者中93例(35%)接受同步放疗。
  • cRT组与no-cRT组分别有69%和60%接受免疫治疗,分别有31%和40%接受靶向治疗。
  • 中位随访6.9个月,cRT组中位OS为16.8个月,no-cRT组为6.9个月。
  • 倾向评分加权后,同步放疗与更长OS相关(HR=0.6,95%CI 0.4-0.8,p=0.007)。
  • 加权后cRT组中位OS为15.3个月,no-cRT组为6.2个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Melanoma brain metastases (MBMs) are historically associated with poor prognosis. Radiation therapy is conventionally associated with a high local control rate. Development of targeted therapy and immunotherapy has improved overall survival (OS) and intracranial response rate, but about 50% of patients failed to respond to these novel therapies. The objective of this study was to assess the impact of combined radiotherapy (cRT) on overall survival in a large multicenter real-life prospective cohort of patients with MBM treated with immunotherapy or targeted therapy. PATIENTS AND METHODS: Clinical data from 262 patients with MBM were collected via MelBase, a French multicentric biobank prospectively enrolling unresectable stage III or IV melanoma. Two groups were defined: patients receiving cRT (cRT group) or not receiving cRT (no-cRT group). Primary end-point was OS. Propensity score weighting was used to correct for indication bias. RESULTS: Among the 262 patients, 93 (35%) received cRT (cRT group). The patients were treated with immunotherapy in 69% and 60% and with targeted therapy in 31% and 40% of the cRT and no-cRT groups, respectively. With a median follow-up of 6.9 months, median OS was 16.8 months and 6.9 months in the cRT and no-cRT groups, respectively. After propensity score weighting, cRT was associated with longer OS (hazard ratio = 0.6, 95% confidence interval: 0.4-0.8; p=0.007). Median OS after ponderation was 15.3 months and 6.2 months in the cRT and no-cRT groups, respectively. CONCLUSION: This study shows that cRT may be associated with a significant decrease of 40% in the risk of death in patients with MBM treated with systemic therapy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Tétu P, Allayous C, Oriano B, et al. Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort. Eur J Cancer. 2019. PMID: 30909072. doi:10.1016/j.ejca.2019.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。